Grundmann E, Roessner A, Ueda Y, Schneider-Stock R, Radig K
Gerhard-Domagk-Institut für Pathologie, Westfälischen Wilhelms-Universität Münster, Germany.
Anticancer Res. 1995 May-Jun;15(3):1023-32.
Since the introduction of standardized chemotherapy protocols of osteosarcoma a lot of new aspects in prognosis and curability of these have best developed. Current subclassification which divided osteosarcoma into a conventional type and eleven important recognizable varieties is one of the reason for this success. Cytological grading also serves as a good indicator for the prognosis and is an important criterion for application of adjuvant chemotherapy. Several structure proteins of the extracellular matrix have gained importance in making the diagnosis of an osteosarcoma. Immunohistochemically and biochemically evaluations could show that different collagenous-proteins can be useful for the differential diagnosis of bone tumors. The integration of molecular pathologic methods into the structural morphologic findings will be helpfull in the identification of mutated structure proteins. Oncogenes and tumor suppressor genes are of major importance for the tumorigenesis of osteosarcoma. The prognostic significance of the inactivation of p53 and RBI gene remains to be elucidated. Resistance to chemotherapy is the major mechanism responsible for the failure of osteosarcoma treatment. The main cause for this failure is multidrug resistance, which is often related to a plasma membrane protein, the P-glycoprotein. Immunohistologic investigations of P-glycoprotein are not sufficient to demonstrate the possible association between overexpression of this protein and tumor progression.
自从引入骨肉瘤标准化化疗方案以来,骨肉瘤预后和可治愈性方面的许多新情况都得到了充分发展。目前将骨肉瘤分为传统型和11种重要可识别类型的亚分类是取得这一成功的原因之一。细胞学分级也是预后的良好指标,是辅助化疗应用的重要标准。细胞外基质的几种结构蛋白在骨肉瘤诊断中变得重要起来。免疫组织化学和生物化学评估表明,不同的胶原蛋白可用于骨肿瘤的鉴别诊断。将分子病理方法与结构形态学发现相结合,将有助于识别突变的结构蛋白。癌基因和肿瘤抑制基因对骨肉瘤的肿瘤发生至关重要。p53和RBI基因失活的预后意义仍有待阐明。对化疗的耐药性是骨肉瘤治疗失败的主要机制。这种失败的主要原因是多药耐药,这通常与一种质膜蛋白即P-糖蛋白有关。对P-糖蛋白的免疫组织学研究不足以证明该蛋白过度表达与肿瘤进展之间的可能关联。